[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-management-of-body-weight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-management-of-body-weight":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644510","phase-3-a-clinical-study-to-evaluate-the-efficacy-and-safety-of-hrs9531-tablets-in-overweight-or-obese-subjects-100644510",false,"NCT07670884","A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects","Inclusion Criteria:\n\n1. Male or female subjects, 18-75 years of age at the time of signing informed consent;\n2. At screening visit, BMI ≥ 28 kg\u002Fm2 or ≥ 24 kg\u002Fm2 with at least one weight-related comorbidity;\n3. Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months;\n4. Able and willing to provide a written informed consent.\n\nExclusion Criteria:\n\n1. Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;\n2. Uncontrollable severe hypertension;\n3. PHQ-9 score ≥ 15;\n4. Medical history or illness that affects body weight;\n5. History of diabetes;\n6. Acute or chronic hepatitis;\n7. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening;\n8. Any organ-system malignancies developed within 5 years;\n9. Acute infection, acute trauma, or medium to large surgery within 30 days prior to screening;\n10. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness, mentally incapacitated or speech-impaired;\n11. Use of any medication or treatment that may have caused significant weight change within 90 days;\n12. History of bariatric surgery;\n13. Known or suspected hypersensitivity to trial product(s) or related products;\n14. History of alcohol and\u002For substance abuse or drug abuse;\n15. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;\n16. Surgery is planned during the trial;\n17. The investigators determined that other conditions were inappropriate for participation in this clinical trial.","ALL","18 Years","75 Years",{"count":20,"type":21},425,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.",[27],"Chronic Management of Body Weight","NOT_YET_RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2027-08",{"name":38,"class":39},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",2]